(LSTA) Lisata Therapeutics, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(LSTA) Lisata Therapeutics, Inc. Complete Analysis Pack
Lisata Therapeutics: Business Model Canvas at a Glance
Unlock the full strategic blueprint behind Lisata Therapeutics, Inc.’s business model. This concise Business Model Canvas reveals how the company creates value, builds partnerships, and positions itself in biotech’s high-stakes market. Ideal for investors, analysts, and strategists who want actionable insight—get the full version to go deeper.
Partnerships
Clinical trial sites and investigators
Lisata Therapeutics, Inc. relies on hospital and physician networks to run its Phase II and Phase IIb studies across HONEDRA, XOWNA, and CLBS201. These sites handle patient screening, enrollment, treatment, and follow-up, which is critical because mid-stage trials depend on fast recruitment and consistent protocol execution.
Contract research organizations 3 programs
Lisata Therapeutics, Inc. relies on contract research organizations to run its 3 programs because clinical-stage biopharma companies usually outsource monitoring, data management, biostatistics, and site coordination. That model is key in multi-center regenerative medicine trials, where CRO networks help keep enrollment, protocol compliance, and reporting aligned across many sites.
Cell manufacturing and GMP partners
Lisata Therapeutics, Inc. relies on cell manufacturing and GMP partners because autologous and other cell-based candidates need controlled processing, testing, and batch release before each dose. In 2025, that outside capacity helped the Company scale without building a full in-house plant, while protecting product quality and release consistency across small, patient-specific lots.
Academic medical centers
Academic medical centers help Lisata Therapeutics reach complex vascular and renal patients, while adding investigator leadership, peer-reviewed publication support, and trial credibility. This matters in rare, hard-to-enroll programs where specialized care sites can speed recruitment and improve data quality.
- Deep disease expertise
- Access to complex patients
- Stronger trial credibility
- Better publication support
Regulators and licensing collaborators
Lisata Therapeutics, Inc. depends on regulators and licensing partners to move its pipeline through FDA and ex-US review paths. HONEDRA has SAKIGAKE designation in Japan, a sign of active regulator engagement that can speed development and support future regional rights or commercialization.
- FDA and ex-US filings shape asset progress
- HONEDRA holds SAKIGAKE in Japan
- Partners can fund and broaden reach
Lisata’s Key Partners and SAKIGAKE Signal Stronger Program Momentum
Lisata Therapeutics, Inc. key partnerships center on CROs, GMP cell makers, academic hospitals, and regulators. These partners support 3 active programs, including HONEDRA, while SAKIGAKE in Japan shows external regulatory backing that can speed review and future partnering.
| Partner | Role | Signal |
|---|---|---|
| CROs | Trial ops | 3 programs |
| GMP makers | Cell supply | 2025 scale-up |
| Regulators | Review | SAKIGAKE |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for Lisata Therapeutics, Inc. covering its oncology-focused value proposition, partners, channels, revenue logic, and strategic risks.
Customizable Excel Spreadsheet
Fast, editable snapshot of Lisata Therapeutics’ pain-point-relief business model for quick review and collaboration.
Reference Sources
Lisata Therapeutics, Inc. Reference Sources provide a credible trail that supports faster due diligence and more confident decision-making.
Activities
Phase II and Phase IIb clinical trials
Lisata Therapeutics, Inc. is focused on late-stage proof, not sales: HONEDRA is in Phase II for critical limb ischemia, XOWNA is in Phase IIb for coronary microvascular dysfunction, and CLBS201 is being studied in chronic kidney disease not on dialysis. These programs sit in the costly mid-to-late clinical zone, where success can shift value fast.
Cell therapy research and development
Lisata Therapeutics, Inc. uses R&D to optimize cellular candidates, test mechanism of action, and move lab findings into translational studies for vascular and renal disease. In FY2025, this work still supported a focused pipeline built around disease-modifying repair, with no product sales and continued investment in development.
Regulatory submissions and compliance
Regulatory submissions and compliance are core for Lisata Therapeutics, Inc., since clinical biopharma work needs active IND maintenance, safety reports within 7 or 15 days for serious events, and timely protocol amendments. One missed filing can pause a trial, so this work keeps studies aligned with ethics boards and health authorities.
Manufacturing process development
Manufacturing process development is a core activity for Lisata Therapeutics, Inc. because reproducible production, testing, storage, and distribution methods are needed to support clinical supply and future commercialization. In FY2025, this work is tightly linked to quality systems, which reduce batch risk and keep the platform usable at scale.
- Clinical supply readiness
- Quality control and release testing
- Storage and distribution stability
- Commercial scale-up support
Business development and partnering
Lisata Therapeutics, Inc. must keep building business development and partnering deals to turn its pre-revenue pipeline into future commercialization paths. That means regional licenses, research alliances, and asset-specific transactions that can bring cash, reduce risk, and expand reach without funding a full sales buildout.
- Secure regional licensing rights
- Use research alliances to de-risk trials
- Monetize assets one by one
- Build future commercialization access
Lisata’s FY2025 Focus: Trials, Regulatory Progress, and Partnerships
Lisata Therapeutics, Inc. key activities in FY2025 were R&D, clinical trial execution, and regulatory upkeep across HONEDRA, XOWNA, and CLBS201. The work is pre-commercial, so each program depends on proof-of-concept data, safety reporting, and disciplined supply chain control.
Business development also matters, since partnerships can help fund trials and widen future access without building a sales force first.
| Key activity | FY2025 focus |
|---|---|
| R&D | Pipeline optimization |
| Clinical ops | Phase II/IIb studies |
| Regulatory | IND and safety filings |
| BD | Licensing and alliances |
What You See Is What You Get
Business Model Canvas
This Lisata Therapeutics, Inc. Business Model Canvas preview is taken directly from the actual document you’ll receive after purchase. It’s not a sample or mockup—what you see here is the same professionally formatted file delivered in full. Once purchased, you’ll get complete access to the exact document, ready to use and edit.
Resources
Three clinical-stage candidates
Lisata Therapeutics, Inc. relies on three clinical-stage candidates, HONEDRA, XOWNA, and CLBS201, as its core key resources. Each program targets a distinct unmet need in vascular or renal disease, so the pipeline spreads risk beyond one asset and supports optionality across multiple readouts.
SAKIGAKE designation for HONEDRA
HONEDRA has received Japan’s SAKIGAKE designation, a status designed to speed development and raise regulatory visibility for innovative therapies. For Lisata Therapeutics, Inc., this makes HONEDRA a key portfolio asset because SAKIGAKE can support priority review and earlier commercial access in Japan, where faster pathways can cut development time by months.
Cell therapy know-how
Lisata Therapeutics, Inc.'s cell therapy know-how is a hard-to-copy asset because it links tissue repair biology with cell-based development, which helps narrow candidate selection, sharpen clinical trial design, and improve manufacturing choices. This matters in a small, research-heavy company: its FY2025 filing still centered on a single lead program, certepetide, showing how much value sits in this specialized know-how.
Clinical data and trial rights
Lisata Therapeutics’ key resources are its Certepetide trial data and trial rights. Ongoing phase 1/2 studies in solid tumors generate proprietary safety and efficacy readouts that shape development and partnering talks; in FY2025, the Company still had no approved product revenue.
Scientific team and public company infrastructure
Lisata Therapeutics, Inc. relies on a small but specialized scientific team plus public-company systems to run clinical-stage work, regulatory filings, and capital access. As of its latest filings, the Company had ongoing R&D spend and cash discipline needs typical of a micro-cap biotech, so finance, legal, and investor relations staff are core resources, not back-office extras.
- Clinical scientists and regulators drive trials
- Finance and legal support SEC compliance
- Investor relations helps fund access
Certepetide and Trial Data Drive Lisata’s Value
Lisata Therapeutics, Inc.’s key resources are its clinical-stage assets, led by certepetide, plus proprietary trial data and trial rights. In FY2025, the Company still had no approved product revenue, so these assets and the scientific team behind them remain the main value drivers.
| Key resource | Evidence |
|---|---|
| Certepetide trial data | Phase 1/2 readouts support development and partnering |
| Specialized team | Runs trials, filings, and funding access |
Value Propositions
Repair damaged tissue
Lisata Therapeutics positions its therapies as regenerative treatments that aim to repair damaged tissue, not just ease symptoms. That matters in chronic disease: its lead program certepetide has moved through Phase 2 studies, showing the company is focused on tissue restoration as a clear differentiator.
Address unmet vascular disease needs
HONEDRA targets critical limb ischemia, the most severe form of peripheral artery disease, which affects about 1% of adults in the U.S. and carries a 1-year amputation or death risk near 25% in advanced cases. XOWNA targets coronary microvascular dysfunction, a condition seen in up to 50% of patients with angina and limited treatment options, highlighting clear unmet need.
Kidney disease without dialysis
CLBS201 targets chronic kidney disease patients before dialysis, opening an earlier-intervention path to slow progression and preserve kidney function. With CKD affecting about 35.5 million U.S. adults, and roughly 1 in 3 at risk of kidney failure, this value proposition focuses on delaying dialysis-linked cost and quality-of-life declines.
Clinical-stage pipeline with 3 assets
Lisata Therapeutics, Inc.’s 3-asset clinical-stage pipeline gives partners more than one shot at success, which helps spread scientific and FDA risk across programs. It also creates several paths for licensing or co-development, so one asset can fail without ending the whole story.
- 3 clinical-stage assets
- Multiple development paths
- Lower program-specific risk
- More licensing options
Cell therapy platform differentiation
Lisata Therapeutics, Inc. builds its value on cell therapies, not small molecules, so the platform is designed to target healing and disease modification through novel biology rather than standard symptom control. As a clinical-stage company with 0 approved products, that differentiation is meant to give patients a new treatment option where current drugs often fall short.
- Cell-based, not small-molecule, approach
- Targets healing and disease change
- Aims to offer a novel option
Lisata’s Regenerative Pipeline Targets Three High-Need Diseases
Lisata Therapeutics, Inc. sells a regenerative, cell-based approach that aims to repair tissue and change disease course, not just ease symptoms. Its pipeline spans HONEDRA, XOWNA, and CLBS201, giving partners multiple shots on goal across severe, hard-to-treat diseases.
| Asset | Need | Value point |
|---|---|---|
| HONEDRA | Critical limb ischemia | Severe PAD, high amputation risk |
| XOWNA | Coronary microvascular dysfunction | Large unmet need |
| CLBS201 | Chronic kidney disease | Earlier intervention before dialysis |
Customer Relationships
Physician investigator collaboration
Physician investigator collaboration is central to Lisata Therapeutics, Inc.'s clinical work because investigators drive site activation, patient enrollment, and data quality. That close scientific tie matters in late-stage drug development, where each enrolled patient and clean data set can shape readouts for Lisata Therapeutics, Inc.'s pipeline, including certepetide, across multiple ongoing studies.
Clinical participant engagement
Clinical participant engagement at Lisata Therapeutics depends on informed consent, repeated follow-up, and tight safety monitoring, especially in cell therapy studies where patients may need multiple assessments. Trust and clear communication matter because trial retention and data quality rise when participants feel supported throughout the study.
Hospital and center partnerships
Lisata Therapeutics, Inc. builds long-term, study-based ties with specialty hospitals and cancer centers that can reach target patients and help run protocols cleanly. These sites also train investigators, which matters in clinical programs where execution quality drives readouts; in its latest public filings, Lisata remained clinical-stage with no product revenue, so these partnerships are a core operating asset.
Partner and regulator communication
Lisata Therapeutics, Inc. relies on frequent technical communication with partners and regulators because it is a development-stage biopharma. It must keep endpoints, safety signals, and manufacturing/CMC updates aligned across ongoing clinical programs, which helps sustain trust and reduce delay risk.
- Frequent endpoint and safety updates
- Regulatory and partner alignment
- Manufacturing/CMC readiness matters
- Supports program continuity
Investor relations
Lisata Therapeutics, Inc. keeps active investor relations through earnings calls, SEC filings, and corporate updates, which is critical for a pre-revenue biotech with no product sales to anchor valuation. Clear disclosure helps shareholders track cash use, trial progress, and dilution risk in real time.
- Regular earnings calls
- SEC filings and updates
- Transparent pre-revenue disclosure
Lisata’s Growth Hinges on Trial Sites, Patients, and Regulators
Lisata Therapeutics, Inc. keeps customer ties centered on trial sites, investigators, regulators, and enrolled patients, because its pipeline still depends on clinical execution, not product sales. As a pre-revenue biotech, clear site support, safety reporting, and investor disclosure are core relationships that keep studies moving and capital access intact.
| Customer | Role |
|---|---|
| Investigators | Enroll patients, run sites |
| Patients | Consent, follow-up, safety data |
| Regulators | Protocol and safety review |
Channels
Clinical trial sites
Clinical trial sites are Lisata Therapeutics, Inc.’s main patient channel: site teams identify, enroll, treat, and monitor participants across its ongoing studies. This lets Lisata Therapeutics, Inc. run current programs with a lean internal footprint while the site network handles the day-to-day execution of each trial.
Medical congresses
Medical congresses let Lisata Therapeutics, Inc. share HONEDRA, XOWNA, and CLBS201 data with clinicians and researchers, building peer validation fast. Major oncology meetings like ASCO draw 40,000+ attendees, so these channels can scale awareness with low-cost scientific reach versus paid media.
Peer-reviewed publications
Peer-reviewed publications help Lisata Therapeutics, Inc. turn trial data into third-party validated evidence, which builds credibility with doctors, payers, and regulators. For a biotech with a small market cap and a limited pipeline, each published study can also support partnering talks and future FDA discussions by showing clear efficacy and safety signals.
Corporate website and investor materials
Lisata Therapeutics, Inc. uses its corporate website and investor materials to share pipeline updates and company news through investor presentations, press releases, and SEC filings. These digital channels keep shareholders and potential partners informed on progress, including quarterly Form 10-Q and annual Form 10-K disclosures on EDGAR.
- Pipeline updates via investor decks
- Press releases for key milestones
- SEC filings for formal disclosures
- Reaches shareholders and partners
Business development outreach
Business development outreach for Lisata Therapeutics, Inc. is mainly direct outreach to biotech, pharma, and regional licensees to negotiate development, manufacturing, or commercialization rights. For a clinical-stage platform, these talks can turn pipeline data into non-dilutive capital and shared execution risk, which matters as development costs keep rising across biotech.
- Direct outreach to biotech and pharma partners
- Can cover development, manufacturing, or commercial rights
- Key channel for a clinical-stage platform
Lisata’s Lean Reach: Trials, Congresses, and Partner Outreach
Lisata Therapeutics, Inc. reaches patients through clinical trial sites, then extends visibility through oncology congresses, peer-reviewed papers, its website, SEC filings, and direct partner outreach. These channels support enrollment, scientific credibility, investor disclosure, and licensing talks while keeping the internal footprint lean.
| Channel | Role | Key data |
|---|---|---|
| Clinical sites | Enroll and monitor patients | Core trial execution |
| ASCO and similar congresses | Scientific reach | 40,000+ attendees |
| Website and SEC filings | Investor disclosure | 10-Q, 10-K, press releases |
| Partner outreach | Licensing talks | Biotech and pharma |
Customer Segments
Critical limb ischemia patients
HONEDRA targets critical limb ischemia patients, the most severe form of peripheral artery disease, where the 1-year risk of major amputation or death remains high and treatment choices are limited. The segment also includes vascular surgeons, interventional cardiologists, and wound-care clinicians who manage these high-risk cases and decide on limb-salvage care.
Coronary microvascular dysfunction patients
XOWNA targets coronary microvascular dysfunction (CMD), a hard-to-diagnose disease of the heart’s small vessels that is seen in up to 50% of patients with angina and non-obstructive coronary arteries. That makes this a large cardiology need, with roughly 8.5 million adults in the U.S. living with symptomatic ischemic heart disease.
Chronic kidney disease patients not on dialysis
CLBS201 targets chronic kidney disease patients before dialysis, a large pool that includes about 1 in 7 U.S. adults with CKD. Nephrology practices are the key setting, and earlier treatment matters because delaying dialysis can avoid annual costs that often exceed $90,000 per patient.
Vascular and renal physicians
Vascular and renal physicians are both users and gatekeepers for Lisata Therapeutics, Inc.: they spot eligible patients, run the studies, and shape who gets the drug after approval. Their clinical reach matters because chronic kidney disease affects about 35.5 million U.S. adults, and peripheral artery disease affects about 8.5 million, giving Lisata a large screened patient pool.
- Identify eligible patients fast
- Guide trial design and endpoints
- Drive post-approval adoption
Biopharma partners and investors
Biopharma partners and investors are key customer segments for Lisata Therapeutics, Inc. because a clinical-stage company needs development capital and deal support before it has broad product sales. They fund trials, de-risk approval, and help turn pipeline assets into commercial value.
- Finance clinical development
- Back strategic licensing deals
- Support approval and launch
- Share pipeline risk
Lisata’s Wide-Traffic Funnel Targets Massive Patient Markets
Lisata Therapeutics, Inc. serves three main customer groups: severe vascular patients and their care teams for HONEDRA, cardiac patients with coronary microvascular dysfunction for XOWNA, and chronic kidney disease patients before dialysis for CLBS201. The funnel is wide: about 8.5 million U.S. adults have symptomatic ischemic heart disease, 35.5 million have CKD, and PAD affects about 8.5 million.
| Segment | Key scale |
|---|---|
| HONEDRA | CLI, high amputation risk |
| XOWNA | CMD up to 50% of angina cases |
| CLBS201 | CKD, 35.5M U.S. adults |
Cost Structure
Clinical trial spend
Clinical trial spend is a major cost in Lisata Therapeutics, Inc.’s Phase II and Phase IIb work, because site payments, monitoring, data management, and safety oversight all rise with study size and complexity. In biotech, each added site and protocol amendment can push trial budgets materially higher, so this line item often drives most of the R&D cash burn.
Manufacturing and CMC costs
Manufacturing and CMC costs are a heavy fixed load for Lisata Therapeutics, Inc. because clinical supply needs process development, testing, storage, and batch-release checks. In 2025, Lisata still had no product revenue, so CMC spend stayed tied to R&D and trial supply, where consistency matters more than scale.
R and D personnel costs
R and D personnel costs at Lisata Therapeutics, Inc. center on scientists, clinicians, regulatory staff, and operations teams, and they stay recurring because payroll, benefits, and hiring support development work each quarter. Public biopharma firms also layer in stock-based compensation, so this cost line is usually cash pay plus equity pay, not just salaries.
Regulatory and quality costs
Regulatory and quality costs cover documentation, audits, QMS upkeep, and outside compliance advice. For Lisata Therapeutics, these costs matter because a single FDA standard NDA user fee in FY2025 is about $4.3 million, so submission planning can move the cost base fast while still supporting therapy advancement.
- Audit and SOP upkeep
- Regulatory filings and reviews
- Consultant and CMC support
- FDA fees can reach $4.3m
Public company overhead
Lisata Therapeutics, Inc. carries public company overhead for legal, accounting, investor relations, and admin work, plus Nasdaq and SEC compliance. That means 4 Form 10-Qs, 1 Form 10-K, and ongoing listing fees each year; Nasdaq annual fees are often in the tens of thousands of dollars, before audit and counsel costs.
- SEC reporting: 5 filings yearly
- Nasdaq fees: ongoing cash drain
- IR, audit, and legal costs stay fixed
Lisata’s cash burn is driven by trials, filings, and fixed public-company overhead
Lisata Therapeutics, Inc.’s cost base is still dominated by clinical trials, CMC, and R&D staff, because it has no product revenue and must fund Phase II/IIb work, supply, and compliance. Public-company overhead stays fixed too, with SEC reporting, Nasdaq fees, legal, audit, and IR costs. FDA user fees in FY2025 were about $4.3 million, which can lift filing costs fast.
| Cost driver | 2025/2026 cue |
|---|---|
| Clinical trials | Largest cash burn |
| FDA NDA fee | About $4.3m |
| SEC filings | 4 Qs, 1 K |
Revenue Streams
No approved product sales
Lisata Therapeutics, Inc. had no approved product sales in fiscal 2025, so revenue was not driven by marketed therapeutics. As a clinical-stage company, it remains in development mode and depends on research-stage funding and any collaboration income rather than commercial drug sales.
Collaboration and licensing fees
Lisata Therapeutics, Inc. can earn collaboration and licensing fees through upfront payments for regional rights, asset access, or technology licenses, which is typical for pre-commercial biotech firms. In its 2025 filings, Lisata had no product sales, so partner cash and license income remain a key near-term funding source before any commercial launch.
Milestone payments
Milestone payments in Lisata Therapeutics, Inc.’s development deals are cash receipts tied to clinical, regulatory, or commercial triggers, so they can fund more R and D without raising capital right away. They also keep partners aligned: Lisata gets paid as programs advance, and collaborators only pay when value is created.
Grant and non-dilutive funding
Lisata Therapeutics, Inc. can use grant and other non-dilutive funding to support research programs without issuing new shares, which helps protect existing ownership and can lower dilution pressure in early-stage development. In biotech, even a single $1 million grant can fund preclinical work or a small clinical study while keeping equity financing needs lower.
- Supports R&D without dilution
- Preserves cash for trials
- Useful before product revenue
Future royalties after approval
If partnered assets reach market, Lisata Therapeutics, Inc. can earn royalties on product sales in licensed territories; in biotech, these are often a 2% to 10%+ share of net sales, but only after approval and launch. This is a standard upside stream, and it creates non-dilutive revenue without Lisata funding the full commercial build.
- Triggered only after approval
- Tied to territorial sales
- High-margin, non-dilutive upside
Lisata’s 2025 Revenue Stayed Pre-Commercial, Led by Collaboration Funding
Lisata Therapeutics, Inc. had no product sales in fiscal 2025, so its revenue streams were still pre-commercial and tied to collaboration fees, upfront license cash, milestone payments, and grants. Any royalty income would come later, only if partnered assets reach approval and generate sales.
| Stream | 2025 status |
|---|---|
| Product sales | None |
| Collab/license fees | Key funding source |
| Milestones | Potential cash inflow |
| Royalties | Future upside |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.